These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19446719)

  • 1. CCR5 pharmacology methodologies and associated applications.
    Mansfield R; Able S; Griffin P; Irvine B; James I; Macartney M; Miller K; Mills J; Napier C; Navratilova I; Perros M; Rickett G; Root H; van der Ryst E; Westby M; Dorr P
    Methods Enzymol; 2009; 460():17-55. PubMed ID: 19446719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
    Meanwell NA; Kadow JF
    Curr Opin Investig Drugs; 2007 Aug; 8(8):669-81. PubMed ID: 17668369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
    Hunt JS; Romanelli F
    Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
    Lorenzen T; Stoehr A; Walther I; Plettenberg A
    Eur J Med Res; 2007 Oct; 12(9):419-25. PubMed ID: 17933723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
    van Lunzen J
    Eur J Med Res; 2007 Oct; 12(9):435-40. PubMed ID: 17933725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
    MacArthur RD; Novak RM
    Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical discovery and development of maraviroc for the treatment of HIV.
    Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M
    Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008.
    Yang H; Rotstein DM
    Expert Opin Ther Pat; 2010 Mar; 20(3):325-54. PubMed ID: 20180619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
    Xu GG; Guo J; Wu Y
    Curr Top Med Chem; 2014; 14(13):1504-14. PubMed ID: 25159165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
    Emmelkamp JM; Rockstroh JK
    Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CCR5 antagonist Maraviroc: effective and well tolerated. "A very promising substance"].
    Zorn F
    MMW Fortschr Med; 2011 May; 153(18):30-1. PubMed ID: 21604590
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.
    Cipriani S; Francisci D; Mencarelli A; Renga B; Schiaroli E; D'Amore C; Baldelli F; Fiorucci S
    Circulation; 2013 May; 127(21):2114-24. PubMed ID: 23633271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
    Rosario MC; Jacqmin P; Dorr P; van der Ryst E; Hitchcock C
    Clin Pharmacol Ther; 2005 Nov; 78(5):508-19. PubMed ID: 16321617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
    Princen K; Schols D
    Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.